½Å¾ÆÁ¾ Ä¡·á ½ÃÀå : À¯Çüº°, ¾àÁ¦ À¯Çüº°, À¯Åë ä³Îº° : Áö¿ªº°
Nephroblastoma Treatment Market, By Type, By Drug Type, By Distribution Channel By Geography
»óǰÄÚµå : 1672945
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ½Å¾ÆÁ¾ Ä¡·á ½ÃÀåÀº 2025³â¿¡´Â 18¾ï 7,000¸¸ ´Þ·¯, 2032³â¿¡´Â 26¾ï 3,000¸¸ ´Þ·¯¿¡ À̸£°í, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 5.0%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 18¾ï 7,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 5.00% 2032³â °¡Ä¡ ¿¹Ãø 26¾ï 3,000¸¸ ´Þ·¯
±×¸². ½Å¾ÆÁ¾ Ä¡·á ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
Nephroblastoma Treatment Market-IMG1

Àª¸§ Á¾¾çÀ¸·Îµµ ¾Ë·ÁÁø ½Å¾ÆÁ¾Àº ¼Ò¾Æ¿¡¼­ ¹ß»ýÇÏ´Â °¡Àå ÈçÇÑ °íÇü Á¾¾ç Áß ÇϳªÀÔ´Ï´Ù. ½Å¾Æ¼¼Æ÷Á¾Àº ½ÅÀå¿¡¼­ ¹ß»ýÇÏ¸ç ¼Ò¾Æ¾Ï ÀüüÀÇ ¾à 6%¸¦ Â÷ÁöÇÕ´Ï´Ù. ½Å¾ÆÁ¾ÀÇ Ç¥ÁØÀûÀÎ Ä¡·á¹ýÀ¸·Î´Â Á¾¾çÀÇ ¼ö¼úÀû ÀýÁ¦°¡ ÇàÇØÁö°í, ±× ÈÄ, ÀÜÁ¸ÇÏ´Â ¾Ï¼¼Æ÷¸¦ Á¦°ÅÇϱâ À§ÇØ È­Çпä¹ýÀÌ ÇàÇØÁö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÃÖ±ÙÀÇ ¼ö¼ú ÀýÂ÷, È­Çпä¹ý ¿ä¹ý ¹× Ç¥Àû ¿ä¹ýÀÇ Áøº¸·Î ½Å¾ÆÁ¾À¸·Î Áø´ÜµÈ ¼Ò¾ÆÀÇ »ýÁ¸À²ÀÌ ÇöÀúÇÏ°Ô °³¼±µÇ¾ú½À´Ï´Ù. ±×·¯³ª ³»¼º Á¾¾çÀÇ °³¹ßÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Å¾ÆÁ¾ Ä¡·á ½ÃÀåÀº Ä¡·á È¿°ú¿Í Ä¡·á ¼ºÀûÀ» Çâ»ó½ÃŰ´Â Çõ½ÅÀûÀÎ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼ºÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

½Å¾ÆÁ¾ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ¼¼°è ¼Ò¾ÆÀÇ ½ÅÀå¾Ï ÀÌȯÀ²ÀÇ »ó½Â¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ¼¼ÀÎÆ® Áêµå ¼Ò¾Æ ¿¬±¸ º´¿øÀÌ 2022³â¿¡ ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é ½Å¾Æ¼¼Æ÷Á¾Àº ½Å»ý¾Æ ¾à 13,000¸í¿¡ 1¸íÀÌ ÀÌȯµÇ¾î ¼Ò¾Æ¾Ï ÀüüÀÇ 6-7%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Áø´Ü ´É·ÂÀÇ Çâ»ó°ú Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, °Ç°­ °ü¸® Á¦°ø¾÷ü´Â À̸¥ ´Ü°è¿¡¼­ ÀÌ ÁúȯÀ» Áø´ÜÇÒ ¼ö ÀÖ¾î È¿°úÀûÀÎ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¼ö¼ú°ú Àå±â°£ÀÇ È­Çпä¹ý°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î Ç¥Àû ¿ä¹ý°ú ¾à¹° Á¶ÇÕ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸´Â ³»¼º Á¾¾çÀ»º¸´Ù È¿À²ÀûÀ¸·Î Ä¡·áÇÒ ¼öÀÖ´Â À¯¸ÁÇÑ ±âȸ¸¦ º¸À¯Çϰí ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

º» º¸°í¼­¿¡¼­´Â ¼¼°è ½Å¾ÆÁ¾ Ä¡·á ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð ¹× CAGRÀ» Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã¿Í ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.

¼¼°è ½Å¾ÆÁ¾ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀº ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î °Ô½ÃµË´Ï´Ù.

º» Á¶»çÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷Àº Merck & Co., È­ÀÌÀÚ»ç, Sun Pharmaceutical Industries Ltd. »ç, Actiza Pharmaceutical Private Limited »ç, Teva Pharmaceutical Industries Ltd. Pharmaceuticals »ç°¡ Æ÷ÇԵ˴ϴÙ.

ÀÌ º¸°í¼­ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° »ó½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è ½Å¾ÆÁ¾ Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ½Å¾ÆÁ¾ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç °áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ½Å¾ÆÁ¾ Ä¡·á ½ÃÀå, À¯Çüº°, 2020³â-2032³â,(10¾ï ´Þ·¯)

Á¦5Àå ½Å¾ÆÁ¾ Ä¡·á ½ÃÀå, ¾àÁ¦ À¯Çüº°, 2020³â-2032³â,(10¾ï ´Þ·¯)

Á¦6Àå ½Å¾ÆÁ¾ Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â,(10¾ï ´Þ·¯)

Á¦7Àå ½Å¾ÆÁ¾ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020³â-2032³â,(10¾ï ´Þ·¯)

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ºÐ¼®°¡ Ãßõ

Á¦10Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Nephroblastoma Treatment Market is estimated to be valued at USD 1.87 Bn in 2025 and is expected to reach USD 2.63 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.0% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.87 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.00% 2032 Value Projection: USD 2.63 Bn
Figure. Nephroblastoma Treatment Market Share (%), By Region 2025
Nephroblastoma Treatment Market - IMG1

Nephroblastoma, also known as Wilms' tumor, is one of the most common solid tumors occurring in children. It originates from nephrogenic rests in the kidneys and accounts for approximately 6% of all childhood cancers. The standard treatment approach for nephroblastoma involves surgical resection of the tumor, often followed by chemotherapy to eliminate any remaining cancer cells. Recent advancements in surgical techniques, chemotherapy regimens as well as targeted therapies have significantly improved the survival rates of children diagnosed with nephroblastoma. However, development of resistant tumors can hamper the market growth. Nephroblastoma treatment market can witness growth due to increasing demand for innovative products that can enhance treatment effectiveness and outcomes.

Market Dynamics

Nephroblastoma treatment market growth is primarily driven by rising incidence of kidney cancer in children worldwide. As per the data published by St. Jude Children's Research Hospital in 2022, nephroblastoma affects approximately 1 in 13,000 newborns and accounts for 6-7% of all childhood cancers. Improved diagnostic capabilities and increasing awareness regarding early detection enables healthcare providers to diagnose the condition at earlier stages, thus, boosting demand for effective therapeutics. However, high costs associated with surgery and prolonged courses of chemotherapy can hamper the market growth. Ongoing research into novel targeted therapies and drug combinations hold promising opportunities for treating resistant tumors more efficiently.

Key features of the study

This report provides in-depth analysis of the global nephroblastoma treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global nephroblastoma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Merck & Co., Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global nephroblastoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephroblastoma treatment market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Nephroblastoma Treatment Market, By Type, 2020-2032, (USD Bn)

5. Nephroblastoma Treatment Market, By Drug Type, 2020-2032, (USD Bn)

6. Nephroblastoma Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

7. Nephroblastoma Treatment Market, By Region, 2020 - 2032, (USD Bn)

8. Competitive Landscape

9. Analyst Recommendations

10. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â